Lv3
210 积分 2024-10-26 加入
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
22天前
已完结
Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)
28天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
29天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
4个月前
已完结
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
5个月前
已完结
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis
5个月前
已完结
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
5个月前
已完结
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
5个月前
已完结
Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment
5个月前
已关闭
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies
5个月前
已完结
皖公网安备34019202002308
